January 16, 2013 at 16:24 PM EST
Regeneron Forms New Base, But It's Late Stage
Regeneron (REGN) has been etching a flat base in the past few weeks, while also finding support at its 10-week moving average. The biotech sports an IBD Composite Rating of 97 out of a best-possible 99, reflecting its many strengths. But the company is a turnaround play, so you won't find an impressive earnings history. Regeneron Pharmaceuticals had been losing money for years until sales began to take off for its eye drug Eylea. Credit Suisse
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here